Bill > HR5260

This bill, the Reduced Costs and Continued Cures Act, aims to lower prescription drug prices in the Medicare and Medicaid programs, improve transparency related to pharmaceutical prices and transactions, lower patients' out-of-pocket costs, and ensure accountability to taxpayers. Key provisions include: - Establishing payment rules for "negotiation-eligible" Medicare Part B drugs, requiring the Secretary to negotiate maximum allowable costs for such drugs. - Making changes to Medicare Part D, such as decreasing reinsurance payments, establishing a manufacturer discount program during the initial and catastrophic phases of coverage, and requiring greater transparency from pharmacy benefit managers. - Implementing a Medicaid drug rebate program for certain drugs with prices increasing faster than inflation. - Addressing intermediaries and promoting drug competition, including by prohibiting "pay-for-delay" agreements and limiting "product hopping". - Establishing a monthly cap on beneficiary out-of-pocket costs for insulin and insulin supplies under Medicare Part D. - Increasing transparency around drug manufacturer pricing and requiring disclosure of pricing information in direct-to-consumer drug ads. The bill also includes provisions related to Medicaid pharmacy and therapeutics committees, oversight of pharmacy benefit managers, and coordination between the FDA and CMS on new medical products.

Business and Industry, Government Affairs, Health and Social Services, Justice

https://www.congress.gov/bill/117th-congress/house-bill/5260/all-info